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showed that variables associated to having a MCS =< 42 points
were: higher ZS and lower FSS of carer. CONCLUSIONS: The
HRQoL of caregivers is slightly worse than that of the general
population of the same age and gender. Physical health status is
more damaged in those caregivers suffering greater burden and
caring for older patients, and mental health status is more
damaged in those suffering greater burden, feeling lower social
support and caring for patients with worse mental health status.
The burden experienced by family carers depends on perceived
social support, age of patient and physical and mental health
status of carer and patient. A signiﬁcant percentage of carers
have depression which is associated to greater burden and lower
social support perceived.
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OBJECTIVES: To describe the process of the adaptation and
standardization of the VSSS-54 (Verona Service Satisfaction
Scale) in Greece. METHODS: The methodology followed was
identical with this of the EPSILON study of schizophrenia. The
Italian Version of the VSSS-54 was ﬁrst translated into Greek,
by two bilingual translators. The resulting translation was then
back-translated into Italian by a professional translator. The
back-translation was checked by the authors of the VSSS and
compared with the original version. The content and the lan-
guage of the ﬁnal Greek translation were discussed in focus
groups, carried out in the Department of Psychiatry of the Uni-
versity General Hospital of Ioannina. The analysis of results of
the ﬁrst group (patients-relatives) as well as the second group
(professionals), allowed us to retrieve useful information related
to the adaptation of the Italian questionnaire VSSS into the
Greek language. The research was carried out in two outpatient
psychiatric services in Athens and in Ioannina. A total of 150
patients were selected (87 women, 63 men), whose age ranged
from 18 to 65 (M = 43.7, SD = 11.45). Among them 64 (43%)
had diagnosis of schizophrenia or other psychosis, 74 (49%)
affective disorder and 10 (6.6%) anxious disorders. The relia-
bility analyses are based on classical test theory. Reliability 
measures used are Cronbach’s a, Cohen’ s weighted k, and the
intra-class correlation coefﬁcient. RESULTS: The a coefﬁcient
for the VSSS total score was 0.917 (95%Cl 0.878–0.948). Test-
retest reliability was proven to be good. CONCLUSIONS: The
psychometric properties of the Greek version of the VSSS are
similar to those of the Italian and the other European versions
of the instrument, outcome which proves that it is a valid and
reliable instrument to use in the Greek context.
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OBJECTIVES: The use of novel antipsychotics (NAs) has
steadily increased and they are now the dominant choice among
antipsychotic agents. Antipsychotics are often prescribed in
elderly patients who become agitated or develop psychotic symp-
toms. New indications, primarily mood disorders, have also 
contributed to growing use. We set out to determine overall pre-
scribing frequency of NAs and changes in patterns of use for spe-
ciﬁc NAs in elderly patients admitted to a psychiatric hospital
over 5-years. METHODS: This was a retrospective analysis of
elderly (≥65 years) patients admitted to a psychiatric hospital
from ﬁscal year (FY) 2000–2004. All NAs prescribed during each
patient admission were identiﬁed from the pharmacy database.
Patient demographics, length of stay, and diagnoses were col-
lected for each patient admission. Descriptive statistics were per-
formed as well as a multivariate logistic regression to determine
factors that inﬂuenced NA prescribing. RESULTS: There were
2179 elderly patients admitted during the 5-year timeframe. The
mean age was 78 years, 63% were female, and 83% were white.
The average length of stay was 21 days and did not differ across
FYs. The proportion of hospital admissions where NAs were pre-
scribed in elderly patients increased signiﬁcantly (p < 0.001) over
the ﬁve-year period from 50% in FY 2000 to 63% in FY 2004.
Prescribing increased the most for quetiapine: 13% in FY 2000
to 27% in FY 2004. Independent factors associated with NA pre-
scribing were female sex (OR = 1.2, p = 0.05), Alzheimer’s
Disease/dementia diagnosis (OR = 1.9, p < 0.001), psychotic 
disorder diagnosis (OR = 4.7, p < 0.001) and increasing FY (OR
= 1.2, p < 0.001). Black race (OR = 0.8) and depression 
diagnosis (OR = 0.5) were associated with a reduced odds of
receiving a NA. CONCLUSIONS: NA prescribing in elderly
inpatients has increased signiﬁcantly in the last ﬁve years, with
quetiapine use increasing the most. Diagnoses of Alzheimer’s
Disease/dementia and psychotic disorders were independent pre-
dictors of NA use.
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It’s widely assumed that patients rehabilitate better in commu-
nity than in inpatient facilities. Moreover deinstitutionalization
saves health care costs. However, deinstitutionalization may
reduce patients’ compliance and entail substantial risks since
patients with schizophrenia have increased risk of becoming
violent and/or committing suicide. OBJECTIVE: Investigate the
relation of risk of harming self and/or others and symptoms in
schizophrenia to improve prevention and diagnosis of patients
who present a risk to society. METHOD: The association
between Positive and Negative Symptom Scale (PANSS) and risk
of harming self/others as measured by Camberwell Assessment
of Need (CAN) score was assessed using logistic regression (N =
171). Standard statistical tests were applied to evaluate the sig-
niﬁcance of relationship between total PANSS, sub-scores (neg-
ative, positive, general psychopathology) and all 30 items, and
risk of harming self/others. Receiver Operating Characteristic
(ROC)-curves were used to assess discrimination. Calibration
was quantiﬁed by the slope of the prognostic index. Model para-
meters were internally validated by bootstrapping. RESULTS:
PANSS is signiﬁcantly associated with risk of harming self/others
with an area under the curve (AUC) of ROC of 0.763. Patients
with total PANSS of 70 and 80 have a 6.8% (95% CI
3.6%–12.4%) and 9.8% (95% CI 5.1%–17.8%) risk of harming
self and/or others respectively. The models including PANSS neg-
ative sub-score or PANSS blunted affect item had an AUC of
ROC of 0.784 and 0.786 respectively for patients’ risk of
harming self and/or others. Discussion: Reducing (negative)
symptoms, especially blunted affect, may reduce patient’s risk of
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harming others and/or themselves. Therefore the importance of
preventing deterioration in a patient’s condition as measured by
PANSS is not only beneﬁcial to the patient but also to society.
Given the difﬁculties in this patient population about maintain-
ing treatment compliance, it may be worthwhile to allocate funds
aimed at reducing symptoms directly or indirectly by improving
compliance.
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OBJECTIVES: Clinical trials have demonstrated the efﬁcacy of
atypical antipsychotic agents in reducing symptoms of schizo-
phrenia. However, the likelihood of sustaining control of schiz-
ophrenic symptoms may depend on treatment persistence. In this
study, we compared treatment persistence between patients who
were initiated on risperidone or olanzapine, the two most widely
prescribed atypical antipsychotic agents. METHODS: We iden-
tiﬁed patients with schizophrenia by ICD-9-CM codes (>1 inpa-
tient or >2 outpatient ICD-9-CM codes >7 days apart) between
July 1, 1998 and June 30, 1999. We further selected those who
were prescribed the target drug during April 1, 1999 through
March 31, 2000 provided that they were not on any antipsy-
chotic agents during the prior six months. Using event history
analysis, we compared treatment persistence in terms of hazard
ratio between olanzapine and risperidone initiators, adjusting for
patient sociodemographic and clinical characteristics. RESULTS:
Following the initiation of the target drug, more patients
switched from risperidone to olanzapine than visa versa. Olan-
zapine initiators had decreased hazards of discontinuation by
14% (unadjusted; p < 0.001) and 12% (adjusted; p = 0.002),
respectively, than risperidone initiators. CONCLUSIONS: Com-
pared with risperidone, olanzapine seems to be better tolerated
by patients as indicated by better treatment persistence. The ini-
tiation of olanzapine may thus increase the likelihood of sus-
taining control of symptoms of schizophrenia. Future research
needs to provide a more comprehensive assessment of treatment
persistence by considering other factors, such as formulary deci-
sion, and other antipsychotic agents in the study and developing
models to assess treatment persistence and switching as two
interdependent competing risks.
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OBJECTIVE: To compare time to ﬁrst psychiatric-related hos-
pitalization and time to ﬁrst medication switch in schizophrenia
patients receiving risperidone long-acting injectable (RLAI) or a
new oral atypical antipsychotic. METHODS: Study sites partic-
ipating in RLAI clinical trials in Canada carried out a retro-
spective chart review of hospitalization and medication use in
schizophrenia patients initiated on RLAI between June 1, 1999
and November 30, 2000. Identical parameters were assessed in
similar patients initiated on a new oral atypical antipsychotic
(control patients) over the same period. RESULTS: Sixty-three
RLAI and 74 control charts were reviewed. Control patients
were signiﬁcantly younger than those in the RLAI group (39.1
years versus 45.3, p = 0.0073) and received risperidone (48.6%),
olanzapine (41.9%) and quetiapine (6.8%) as the oral atypical
antipsychotic. Over the assessment periods, 56.8% of control
patients were hospitalized versus 4.8% of RLAI patients (p <
0.0001). For those patients hospitalized, time to ﬁrst hospital-
ization was marginally but not signiﬁcantly lower for RLAI
patients at 13.8 months compared to 19.3 months for the control
patients, respectively (p = 0.6365). However, control patients
had a signiﬁcantly increased risk of hospitalization, as indicated
by Kaplan Meier survival analysis (p < 0.0001 by log-rank test).
There was no signiﬁcant difference in the number of patients
switching medication (47.6% and 59.5% for RLAI and controls
respectively, p = 0.1742) or in time to ﬁrst medication switch
(39.71 and 34.52 months, log-rank p = 0.2076). However, time
to relapse, deﬁned as a hospitalization or a medication switch,
was signiﬁcantly different (p = 0.0004 by log-rank test) with
50% of controls reaching this endpoint at 18 months versus 60
months for RLAI patients. CONCLUSIONS: This study pro-
vides evidence that RLAI is superior to oral atypicals in reduc-
ing hospitalizations. Furthermore, by virtue of its bi-weekly
administration, RLAI offers atypical therapy without the serious
compliance issues associated with an oral medication, providing
clinical and potential economic advantages.
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OBJECTIVE: To compare psychiatric-related hospitalization
and medication use in patients with schizophrenia, before and
after initiation of risperidone long-acting injectable (RLAI)
therapy. METHODS: Schizophrenia patients who participated in
RLAI clinical trials in Canada were identiﬁed and their charts
were retrospectively reviewed to assess hospitalization and med-
ication use over identical periods before and after the initiation
of RLAI therapy. RESULTS: Sixty-three charts were reviewed.
The mean RLAI treatment period was 40.3 months with 52.4%
of patients still receiving therapy at the time of the chart audit.
The pre- and post-RLAI assessment periods were identical at
39.4 and 40.3 months, respectively (p = 0.8293). There were sta-
tistically signiﬁcant differences in hospitalization before and after
the initiation of RLAI therapy. After initiation of RLAI therapy
fewer patients were hospitalized (52.4% prior to RLAI versus
4.8% during RLAI treatment, Relative Risk = 10.9, p < 0.0001),
fewer patients had more than one hospitalization (24% versus
0%, p < 0.0001), the total duration of hospitalization days
decreased by 99% (1558 versus 23, p < 0.0001), the number of
hospitalizations per patient decreased by 89% (0.9 versus 0.1, 
p < 0.0001) and duration of hospitalization decreased by 98%
(24.7 days per patient versus 0.4, p < 0.0001). Furthermore, anti-
cholinergic and anxiolytic use decreased from 81% of patients
to 64% (p = 0.0459) and 57% to 35% (0.0198), respectively,
with RLAI while sedative use was not signiﬁcantly different
(22% and 16% of patients used sedatives pre- and post-RLAI,
respectively, p = 0.4967). CONCLUSIONS: RLAI had a signiﬁ-
cant impact on hospitalization of schizophrenia patients, offer-
ing a clear clinical beneﬁt compared to traditional antipsychotic
therapy. In addition, the signiﬁcant decrease in hospitalization
